Structure Therapeutics (NASDAQ:GPCR) Releases Earnings Results, Beats Expectations By $999.35 EPS

Structure Therapeutics (NASDAQ:GPCR) issued its quarterly earnings results on Thursday. The company reported $999.00 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $999.35, reports.

Structure Therapeutics Trading Down 2.7%

Structure Therapeutics stock traded down $1.78 during mid-day trading on Thursday, hitting $64.75. The company’s stock had a trading volume of 939,537 shares, compared to its average volume of 880,593. The stock’s fifty day moving average price is $75.45 and its two-hundred day moving average price is $46.22. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $94.90.

Analyst Upgrades and Downgrades

Several research firms have weighed in on GPCR. Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. HC Wainwright lifted their target price on Structure Therapeutics from $60.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Jefferies Financial Group set a $125.00 target price on Structure Therapeutics and gave the company a “buy” rating in a report on Thursday, December 11th. BMO Capital Markets reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, January 6th. Finally, Morgan Stanley upped their price target on shares of Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $106.20.

Institutional Trading of Structure Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. State of Wyoming bought a new position in Structure Therapeutics during the second quarter valued at about $28,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Structure Therapeutics in the 4th quarter valued at about $127,000. Raymond James Financial Inc. bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $129,000. Cibc World Market Inc. bought a new position in Structure Therapeutics during the fourth quarter worth about $226,000. Finally, Engineers Gate Manager LP acquired a new position in Structure Therapeutics in the 2nd quarter worth $329,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.